Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Puma Biotechnology (PBYI)

Puma Biotechnology (PBYI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 139,410
  • Shares Outstanding, K 49,088
  • Annual Sales, $ 235,640 K
  • Annual Income, $ 21,590 K
  • EBIT $ 32 M
  • EBITDA $ 44 M
  • 60-Month Beta 1.09
  • Price/Sales 0.57
  • Price/Cash Flow 3.94
  • Price/Book 1.89

Options Overview Details

View History
  • Implied Volatility 104.86% ( +25.15%)
  • Historical Volatility 92.96%
  • IV Percentile 53%
  • IV Rank 18.59%
  • IV High 499.61% on 06/20/24
  • IV Low 14.72% on 08/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 31
  • Volume Avg (30-Day) 71
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 2,849
  • Open Int (30-Day) 2,524

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.11
  • Number of Estimates 3
  • High Estimate 0.18
  • Low Estimate 0.07
  • Prior Year 0.26
  • Growth Rate Est. (year over year) -57.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.32 +28.45%
on 11/18/24
3.51 -15.10%
on 11/08/24
+0.17 (+6.05%)
since 10/21/24
3-Month
2.22 +33.93%
on 09/06/24
3.51 -15.10%
on 11/08/24
+0.28 (+10.37%)
since 08/21/24
52-Week
2.22 +33.93%
on 09/06/24
7.73 -61.45%
on 02/15/24
-0.87 (-22.60%)
since 11/21/23

Most Recent Stories

More News
PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer

Puma Biotechnology, Inc. PBYI announced that it has initiated the phase II ALISCA-Breast1 study evaluating its pipeline candidate, alisertib, for the treatment of patients with metastatic breast cancer.The...

IMCR : 32.43 (+0.03%)
PBYI : 2.94 (+3.52%)
CSTL : 28.92 (+1.65%)
SPRO : 1.1650 (-2.92%)
PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up

Puma Biotechnology, Inc. PBYI reported third-quarter 2024 adjusted earnings of 45 cents per share, which beat the Zacks Consensus Estimate of 35 cents. In the year-ago quarter, the company had reported...

FOLD : 9.55 (-0.42%)
IMCR : 32.43 (+0.03%)
PBYI : 2.94 (+3.52%)
CSTL : 28.92 (+1.65%)
Puma Biotech: Q3 Earnings Snapshot

Puma Biotech: Q3 Earnings Snapshot

PBYI : 2.94 (+3.52%)
Puma Biotech: Q2 Earnings Snapshot

Puma Biotech: Q2 Earnings Snapshot

PBYI : 2.94 (+3.52%)
Puma Biotech: Q1 Earnings Snapshot

Puma Biotech: Q1 Earnings Snapshot

PBYI : 2.94 (+3.52%)
Puma Biotech: Q4 Earnings Snapshot

Puma Biotech: Q4 Earnings Snapshot

PBYI : 2.94 (+3.52%)
Puma Biotech: Q3 Earnings Snapshot

Puma Biotech: Q3 Earnings Snapshot

PBYI : 2.94 (+3.52%)
Puma Biotech: Q2 Earnings Snapshot

Puma Biotech: Q2 Earnings Snapshot

PBYI : 2.94 (+3.52%)
Five Top Companies Fighting for the Treatment of Metastatic Breast Cancer

A significant medical breakthrough is needed in the fight against metastatic breast cancer. According to the American Cancer Society, more than 3.1 million women in the United States have a history of...

LLY : 748.71 (-0.62%)
PBYI : 2.94 (+3.52%)
GILD : 89.81 (+1.33%)
IMGN : 31.23 (unch)
BCTX : 0.7480 (+24.19%)
BCT.TO : 1.04 (+22.35%)
There are Positive Developments in the Treatment of Metastatic Breast Cancer

A significant medical breakthrough is desperately needed in the fight against metastatic breast cancer. As it stands right now, metastatic breast cancer has no cure and has proven resistant to many cancer...

LLY : 748.71 (-0.62%)
PBYI : 2.94 (+3.52%)
GILD : 89.81 (+1.33%)
IMGN : 31.23 (unch)
BCTX : 0.7480 (+24.19%)
BCT.TO : 1.04 (+22.35%)

Business Summary

Puma Biotechnology, Inc. is a small cancer biotech whose only marketed product, Nerlynx (neratinib) was launched in the United Statesfor the treatment of early stage HER2-positive breast cancer in patients who have been previously treated with Roche's Herceptin-based adjuvant therapy. The drug was also...

See More

Key Turning Points

3rd Resistance Point 3.11
2nd Resistance Point 2.99
1st Resistance Point 2.91
Last Price 2.94
1st Support Level 2.71
2nd Support Level 2.59
3rd Support Level 2.51

See More

52-Week High 7.73
Fibonacci 61.8% 5.63
Fibonacci 50% 4.98
Fibonacci 38.2% 4.33
Last Price 2.94
52-Week Low 2.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar